Semaglutide's Role in Modulating the Brain-Heart Axis: Implications for Obesity and Alzheimer’s Disease Co-management
DOI:
https://doi.org/10.47941/ijhmnp.3122Keywords:
Semaglutide, Brain-Heart Axis, Obesity, Alzheimer’s Disease, GLP-1 Receptor Agonists, Neurocardiology, Comorbidity ManagementAbstract
Purpose: This study aimed to investigate the potential of Semaglutide, a GLP-1 receptor agonist, in modulating the brain-heart axis and offering a dual-therapeutic benefit for patients with comorbid obesity and Alzheimer’s disease.
Methodology: A comprehensive review of recent clinical trials, experimental studies, and mechanistic analyses published between 2020 and 2025 was conducted using data sourced from PubMed, Scopus, and Embase. The inclusion criteria focused on studies exploring Semaglutide's effects on neuroinflammation, cardiovascular function, cognition, and metabolic parameters. Both qualitative synthesis and quantitative meta-analyses were applied. Additional data visualization techniques were employed to present key findings through tables, charts, and pathway diagrams.
Findings: The analysis revealed that Semaglutide reduced key pro-inflammatory biomarkers (e.g., IL-6, TNF-α), improved heart rate variability, and showed neuroprotective effects by enhancing cerebral blood flow and preserving cognitive function in early-stage AD patients. Clinically, Semaglutide led to substantial weight loss, improved glycemic control, and favorable cardiovascular outcomes. Meta-analytic data showed statistically significant improvements in cognitive assessments (MMSE and MoCA scores) and cardiometabolic markers in dual-diagnosis patients, indicating the agent’s cross-system therapeutic relevance.
Unique Contribution to Theory, Policy, and Practice: This study provides a novel framework for understanding the role of GLP-1 receptor agonists in modulating the brain-heart axis and managing dual-pathology in metabolic and neurodegenerative diseases. It offers translational insights for clinicians seeking integrated treatment strategies and emphasizes the importance of repositioning Semaglutide as a potential therapeutic candidate beyond diabetes and obesity, particularly in neurocardiometabolic comorbidity management. Future policy and clinical trials should focus on long-term safety, patient stratification, and the incorporation of brain-heart biomarkers into therapeutic decision-making.
Downloads
References
Alzheimer’s Disease International. World Alzheimer Report 2022–Life after diagnosis: Navigating treatment, care and support. Alzheimer Society of Canada, 2022.
Amadi, E. E. In Vitro Evaluation Of Cytogenetic Damage By Graphene Oxide (15-20 Sheets) Nanomaterials In Human Blood Leukocytes From Healthy Individuals And Pulmonary Disease Patients Diagnosed With Asthma, Copd And Lung Cancer.
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., ... & Still, C. D. (2015). Pharmacological management of obesity: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342-362.
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., ... & Giorgino, F. (2022). Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovascular diabetology, 21(1), 162.
Cheng, X., Zhang, J., Jing, H., Qi, Y., Yan, T., Wu, B., ... & Jia, Y. (2021). Pharmacokinetic Differences of Grape Seed Procyanidins According to the Gavage Administration between Normal Rats and Alzheimer's Disease Rats. Current Pharmaceutical Analysis, 17(1), 119-128.
Chin, R., Nagaoka, S., Nakasawa, H., Tanaka, Y., & Inagaki, N. (2023). Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study. Journal of Diabetes Investigation, 14(2), 247-258.
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., ... & Haupt, A. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular metabolism, 18, 3-14.
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019). Alzheimer's disease drug development pipeline: 2019. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 5, 272-293.
De Felice, F. G., & Lourenco, M. V. (2015). Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer’s disease. Frontiers in aging neuroscience, 7, 94.
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell metabolism, 27(4), 740-756.
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. bmj, 315(7109), 629-634.
Emmerzaal, Tim L., Amanda J. Kiliaan, and Deborah R. Gustafson. "2003-2013: a decade of body mass index, Alzheimer's disease, and dementia." Journal of Alzheimer’s disease 43.3 (2014): 739-755.
Farruggia, M. C., & Small, D. M. (2019). Effects of adiposity and metabolic dysfunction on cognition: A review. Physiology & behavior, 208, 112578.
Gault, V. A., Flatt, P. R., & O’Harte, F. P. (2003). Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochemical and biophysical research communications, 308(2), 207-213.
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., ... & Rungby, J. (2016). In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Frontiers in aging neuroscience, 8, 198350.
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., ... & Shapiro, A. E. (2021). Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. New England Journal of Medicine, 385(21), 1941-1950.
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj, 336(7650), 924-926.
Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., ... & Gao, Q. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(12), 1645-1653.
Hansen, H. H., Fabricius, K., Barkholt, P., Niehoff, M. L., Morley, J. E., Jelsing, J., ... & Vrang, N. (2015). The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, 46(4), 877-888.
Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. bmj, 327(7414), 557-560.
Hunter, K., & Hölscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC neuroscience, 13(1), 33.
Kell, D. B., Laubscher, G. J., & Pretorius, E. (2022). A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochemical Journal, 479(4), 537-559.
Lai, S. W., Chen, M. Y., Bamodu, O. A., Hsieh, M. S., Huang, T. Y., Yeh, C. T., ... & Cherng, Y. G. (2021). Exosomal lncRNA PVT1/VEGFA axis promotes colon cancer metastasis and stemness by downregulation of tumor suppressor miR‐152‐3p. Oxidative Medicine and Cellular Longevity, 2021(1), 9959807.
Li, Y., Zhang, Y., Timofte, R., Van Gool, L., Yu, L., Li, Y., ... & Wang, X. (2023). NTIRE 2023 challenge on efficient super-resolution: Methods and results. In Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (pp. 1922-1960).
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., ... & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj, 339.
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., ... & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The lancet, 396(10248), 413-446.
Mahley, R. W., & Huang, Y. (2012). Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron, 76(5), 871-885.
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ... & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
Nguyen, T. T., Nguyen-Thi, P. T., Nguyen, T. H. A., Ho, T. T., Tran, N. M. A., Van Vo, T., & Van Vo, G. (2023). Recent advancements in nanomaterials: a promising way to manage neurodegenerative disorders. Molecular Diagnosis & Therapy, 27(4), 457-473.
Obata, Y., Castaño, Á., Boeing, S., Bon-Frauches, A. C., Fung, C., Fallesen, T., ... & Pachnis, V. (2020). Neuronal programming by microbiota regulates intestinal physiology. Nature, 578(7794), 284-289.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... & Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj, 372.
Regen, F., Hellmann-Regen, J., Costantini, E., & Reale, M. (2017). Neuroinflammation and Alzheimer's disease: implications for microglial activation. Current Alzheimer Research, 14(11), 1140-1148.
Santos-Gallego, C. G., Garcia-Ropero, A., Mancini, D., Pinney, S. P., Contreras, J. P., Fergus, I., ... & Badimon, J. J. (2019). Rationale and design of the EMPA-TROPISM trial (ATRU-4): are the “cardiac benefits” of empagliflozin independent of its hypoglycemic activity?. Cardiovascular drugs and therapy, 33(1), 87-95.
Siddeeque, N., Hussein, M. H., Abdelmaksoud, A., Bishop, J., Attia, A. S., Elshazli, R. M., ... & Toraih, E. A. (2024). Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study. International Immunopharmacology, 143, 113537.
Smidt, N., Rutjes, A. W., Van Der Windt, D. A., Ostelo, R. W., Reitsma, J. B., Bossuyt, P. M., ... & De Vet, H. C. (2005). Quality of reporting of diagnostic accuracy studies. Radiology, 235(2), 347-353.
Thayer, J. F., & Lane, R. D. (2009). Claude Bernard and the heart–brain connection: Further elaboration of a model of neurovisceral integration. Neuroscience & Biobehavioral Reviews, 33(2), 81-88.
Thayer, J. F., Yamamoto, S. S., & Brosschot, J. F. (2010). The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. International journal of cardiology, 141(2), 122-131.
Vieira, J. R., Elkind, M. S., Moon, Y. P., Rundek, T., Boden-Albala, B., Paik, M. C., ... & Wright, C. B. (2011). The metabolic syndrome and cognitive performance: the Northern Manhattan Study. Neuroepidemiology, 37(3-4), 153-159.
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
World Health Organization. (2023). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Zulli, R., Nicosia, F., Borroni, B., Agosti, C., Prometti, P., Donati, P., ... & Padovani, A. (2005). QT dispersion and heart rate variability abnormalities in Alzheimer's disease and in mild cognitive impairment. Journal of the American Geriatrics Society, 53(12), 2135-2139.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Abhimanyu Gupta
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
